GRI Bio’s (GRI) Buy Rating Reiterated at HC Wainwright

by · The Markets Daily

HC Wainwright restated their buy rating on shares of GRI Bio (NASDAQ:GRI – Free Report) in a research report sent to investors on Thursday morning,Benzinga reports. The firm currently has a $10.00 target price on the stock.

Several other equities research analysts have also recently commented on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GRI Bio in a research report on Friday, July 17th. Ascendiant Capital Markets reduced their price target on shares of GRI Bio from $40.00 to $32.00 and set a “buy” rating on the stock in a research report on Monday, June 1st. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $21.00.

Read Our Latest Research Report on GRI Bio

GRI Bio Trading Down 2.1%

Shares of GRI opened at $1.90 on Thursday. GRI Bio has a 12-month low of $1.36 and a 12-month high of $64.12. The company has a market cap of $4.16 million, a PE ratio of -0.05 and a beta of -1.24. The stock has a 50-day moving average price of $1.76 and a 200-day moving average price of $2.10.

GRI Bio (NASDAQ:GRI – Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.91) EPS for the quarter, topping analysts’ consensus estimates of ($1.19) by $0.28. As a group, analysts predict that GRI Bio will post -3.75 earnings per share for the current year.

About GRI Bio

(Get Free Report)

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.

Further Reading